Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

Selecta Biosciences Inc SELB and Ginkgo Bioworks Holdings Inc DNA have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases.
The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.
Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases.
Under the terms of the collaboration, Ginkgo is eligible for upfront R&D fees and milestones, including certain milestone payments in Selecta common stock, clinical and commercial milestone payments of up to $85M in cash.
Related: Selecta In-Licenses Rights To IgG Protease Platform.
Price Action: SELB shares are up 7.24% at $3.83, and DNA shares are up 6.09% at $15.15 during the market session on the last check Tuesday.